CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06422143
Title field or adapter rule: {'original_value': 'Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-11-01T01:03:03.372390+00:00
Published At: 2026-10-29T00:00:00+00:00
Record Updated At: 2026-10-29
Source Retrieved At: 2026-11-01T01:03:02.902675+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Non-small Cell Lung Cancer", "NSCLC"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-29", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06422143"
protocolSection.identificationModule.officialTitle: "Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Maintenance Arm A: Pembrolizumab + sac-TMT', 'Maintenance Arm B: Pembrolizumab Monotherapy'], 'description': 'Intravenous (IV) infusion', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Maintenance Arm A: Pembrolizumab + sac-TMT'], 'description': 'IV infusion', 'name': 'sac-TMT', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Maintenance Arm A: Pembrolizumab + sac-TMT', 'Maintenance Arm B: Pembrolizumab Monotherapy'], 'description': 'Participants receive AUC 6 or AUC 5 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.', 'name': 'Carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Maintenance Arm A: Pembrolizumab + sac-TMT', 'Maintenance Arm B: Pembrolizumab Monotherapy'], 'description': 'Participants receive 200 mg/m\\^2 or 175 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.', 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Maintenance Arm A: Pembrolizumab + sac-TMT', 'Maintenance Arm B: Pembrolizumab Monotherapy'], 'description': 'Participants receive 100 mg/m\\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.', 'name': 'Nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.